Daptomycin Susceptibility of Group B Streptococcus.

This study aimed to analyze the daptomycin susceptibility among the 1,046 clinical GBS isolates that were recovered since the approval of daptomycin in Japan. MICs of daptomycin for the 1,046 clinical isolates were determined by the microdilution method recommended by the CLSI. The MIC range was 0.12-1 µg/ml, and the MIC50 and MIC90 were 0.5 µg/ml and 1 µg/ml, respectively. None of the GBS isolates evaluated in this study was non-susceptible to daptomycin. Therefore, at present, daptomycin might be considered as a new option to treat GBS infections, especially, multidrug-resistant PRGBS infections. PMID: 32999183 [PubMed - as supplied by publisher]
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Jpn J Infect Dis Source Type: research